US Bancorp’s Stoke Therapeutics STOK Stock Holding History
Bought
Maintained
Sold
Other funds holding STOK
RI
LCM
RG
BBA
BI
US Bancorp's STOK Position: Q1 2026 in Review
US Bancorp increased its Stoke Therapeutics (STOK) stake by 8.6% in Q1 2026, buying an estimated $689 and bringing the position to 265 shares worth $8.63K. The position accounts for ﹤0.01% of the portfolio, ranked #3407.
US Bancorp first reported a position in STOK in Q1 2020 and has held it in 19 quarters since. The position peaked at $74.6K in Q1 2025. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.
- US Bancorp held 265 shares of Stoke Therapeutics worth $8.63K as of Q1 2026.
- US Bancorp bought 21 Stoke Therapeutics shares in Q1 2026, an estimated $689.
- Stoke Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q1 2026, its #3407 holding.
- US Bancorp first reported a position in Stoke Therapeutics in Q1 2020 and has held it in 19 quarters since.
- US Bancorp's Stoke Therapeutics position peaked at $74.6K in Q1 2025.
- 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.
Based on US Bancorp's 13F filing for Q1 2026, filed 15 May 2026.